Mizuho said the FDA approval of Merrimack's Onivyde for the treatment of advanced pancreatic cancer with a Black Box warning for diarrha and neutropenia was not unexpected and is in line with labeling for Camptosar. The bank expects Onivyde to be availabel in the next week in the United States. Gemcitabine-based therapy is a standard of care and is used in adjuvant, first and later lines of treatment. so the "post-gemctiabine" labeling provides a greater market opportunity than a more traditional "second-line" usage would, according the the firm's analyst.